Anbenitamab is a novel HER2-targeted biparatopic bispecific antibody that simultaneously binds to two distinct, non-overlapping epitopes (domains II and IV) of the human epidermal growth factor receptor 2 (HER2).
Anbenitamab is a HER2-directed, biparatopic bispecific monoclonal antibody. It binds two nonoverlapping HER2 epitopes, inhibits HER2 signaling, and may enhance antibody-dependent cellular cytotoxicity.
Mechanism of Action
Dual Epitope Binding: Targets the same extracellular regions as trastuzumab (Domain IV) and pertuzumab (Domain II), providing a more comprehensive blockade of HER2 signaling and overcoming certain mechanisms of resistance.
It induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity, leading to tumor cell apoptosis and inhibition of cell proliferation.
Gastric and Gastroesophageal Junction (GEJ) Cancer: for adult patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who previously received a trastuzumab-containing regimen.
Breast Cancer: Evaluated in late-stage clinical trials where anbenitamab-based regimens significantly improved total pathological complete response (tpCR) rates compared to standard-of-care HER2 regimens in early or locally advanced HER2-positive breast cancer.
It is distinct from zanidatamab, although both target HER2 biparatopically.
Gastric and gastroesophageal-junction cancer: studied with chemotherapy in HER2-positive advanced disease after first-line treatment failure.
In the randomized KN026-001 phase 2/3 program, the reported median progression-free survival was 7.1 versus 2.7 months with chemotherapy alone and median overall survival was 19.6 versus 11.5 months.
HER2-positive breast cancer: phase 3 studies have evaluated anbenitamab with chemotherapy, including neoadjuvant treatment. In the reported Neo-Healer randomized phase 3 study, total pathologic complete response was 62.4% versus 51.2% compared with standard trastuzumab/pertuzumab-based chemotherapy.
The gastric-cancer development regimen reported intravenous anbenitamab 30 mg/kg every 3 weeks with chemotherapy.
Anbenitamab is an investigational-to-regionally approved HER2 bispecific antibody being developed mainly for HER2-positive gastric/GEJ and breast cancer.
